Zestril - referral

Current status

European Commission final decision

Overview

Zestril contains an active substance named lisinopril, an angiotensin converting enzyme inhibitor. The mechanism through which lisinopril lowers blood pressure is believed to be primarily via the suppression of the renin-angiotensin-aldosterone system. Zestril (a medicinal product containing lisinopril) was first authorised in 1984 in the treatment of essential hypertension and renovascular hypertension and in the treatment of congestive heart failure as adjunctive treatment with diuretics and, where appropriate, digitalis.

Different Summaries of Product Characteristics (SPC) had been authorised, based on national, divergent decisions from the authorisations in the EU Member States. On 18 July 2002, The Netherlands presented to the EMEA (See Annex I) a referral under Article 30 of Directive 2001/83/EEC.

The referral procedure started on 24 July 2002 in order to resolve divergences amongst the nationally authorised SPCs and to harmonise the SPCs within the Member States and Norway.

During its September 2003 meeting, the CPMP, having considered the Rapporteur and the Co- Rapporteur assessment reports, the scientific discussion within the Committee and the comments from the Marketing Authorisation Holders (MAH), was of the opinion that the benefit/risk ratio of lisinopril is considered to be favourable in the following indications:

Treatment of hypertension, symptomatic heart failure, acute myocardial infarction (for the short-term 6 weeks), treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction) and for the renal complications of diabetes mellitus (treatment of renal disease in hypertensive patients with type 2 diabetes mellitus and incipient nephropathy).

A positive opinion was therefore adopted on 25 September 2003, recommending the harmonisation of the SPC for Zestril and associated names.

The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amended SPC in Annex III.

The European Commission issued a Decision on 16 January 2004.

Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Zestril and associated names (see Annex I) International Non-Proprietary Name (INN): lisinopril: Background information

AdoptedReference Number: CPMP/423/04

Key facts

About this medicine

• Approved name:
  Zestril
• International non-proprietary name (INN) or common name:
  lisinopril

About this procedure

• Current status:
  European Commission final decision
• Reference number:
  CPMP/423/04
• Type:
  Article 30 referrals

  This type of referral is triggered when Member States have adopted different decisions over the years for some medicines (e.g. different indications, contraindications or posology) and there is a need to harmonise across the EU.

Key dates and outcomes

• CHMP opinion date:
  25/09/2003
• EC decision date:
  16/01/2004

All documents

Zestril - Article 30 referral - Annex I, II, III

Adopted

Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Zestril and associated names (see Annex I) International Non-Proprietary Name (INN): lisinopril: Background information

AdoptedReference Number: CPMP/423/04

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

• Overview - lay-language summary of the stage of the procedure
• Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
• Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
• List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
• Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
• List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
• List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
• Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
• Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
• Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
• Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
• Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
• Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
• Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
• Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

Note that older documents may have different titles.